Scarica l'app Stockscreener
3.00
2.39%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
ZNTLZentalis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Athersys (NASDAQ:ATHX) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head to Head Review - Defense World
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Kilgore News Herald
Zentalis Pharmaceuticals expands leadership team - Investing.com India
Zentalis Pharmaceuticals Appoint Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer - citybiz
Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewswire
Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments - StockTitan
The time has not yet come to remove your chips from the table: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd., expected to drive Osteosarcoma market - Barchart
Osteosarcoma Market expected to rise | AlaMab Therapeutics, - openPR
Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Grants 4.5M Stock Options to New CEO, CMO & Employees | ZNTL Stock News - StockTitan
ZNTL (Zentalis Pharmaceuticals) EBITDA : $-207.96 Mil (TTM As of Sep. 2024) - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat
Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
Brokers Set Expectations for ZNTL Q3 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for ZNTL FY2024 Earnings - MarketBeat
Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00 - MarketBeat
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Buy Rating at HC Wainwright - MarketBeat
Wedbush Has Positive Estimate for ZNTL FY2024 Earnings - MarketBeat
Citadel Advisors LLC Adjusts Stake in Zentalis Pharmaceuticals I - GuruFocus.com
ZNTL (Zentalis Pharmaceuticals) Enterprise Value : $282.73 Mil (As of Nov. 14, 2024) - GuruFocus.com
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift - TipRanks
Zentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib Sharpen - MarketWatch
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Zentalis Pharma Reshapes Leadership, Advances Cancer Drug Azenosertib Toward Key Trials | ZNTL Stock News - StockTitan
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL): Worth A Small Bite At $3.81 - Stocks Register
Eventide Asset Management's Strategic Reduction in Zentalis Phar - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Zentalis Pharmaceuti - GuruFocus.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Zentalis stock hits 52-week low at $2.82 amid market challenges - Investing.com Canada
Undervalued Opportunities: US Penny Stocks To Watch In October 2024 - Simply Wall St
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings - Yahoo Finance
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - SETE News
Zentalis Pharmaceuticals Inc [ZNTL] Stock sold by Insider Vultaggio Vincent for $5098.0 - Knox Daily
Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News - Yahoo Finance
Balance Sheet Insights: Zentalis Pharmaceuticals Inc (ZNTL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Zentalis Pharmaceuticals Inc (ZNTL)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 26.2% - MarketBeat
ZNTL Shares Experience Decline in Value - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from Brokerages - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):